Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
Research

Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010

Sarah E. SmithComments to Author , Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, and J. Peter Cegielski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.E. Smith, J. Ershova, E. Kurbatova, J.P. Cegielski); Arkhangelsk Regional Tuberculosis Dispensary, Arkhangelsk, Russia (N. Vlasova, E. Nikishova, I. Tarasova, P. Eliseev, A.O. Maryandyshev); Northern State Medical University, Arkhangelsk (A.O. Maryandyshev); State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia (I.G. Shemyakin)

Main Article

Table 4

Risk factors for acquiring extensive drug resistance during MDR TB treatment, 164 patients, Arkhangelsk, Russia, 2005–2010*

Variable† Total Acquired extensive drug resistance, no. (%)
 p value‡
Yes No
Treated with ≥3 effective drugs
Yes 129 1 (0.8) 128 (99.2) 0.03
No 35 3 (8.6) 32 (91.4)
Ever received effective FQ§
Yes 160 3 (1.9) 157 (98.1) 0.07
No 3 1 (33.3) 2 (66.7)
Body mass index <18.5 at MDR TB diagnosis
Yes 36 3 (8.3) 33 (91.7) 0.03
No 128 1 (0.8) 127 (99.2)
Baseline OFX susceptibility result
Resistant 3 1 (33.3) 2 (66.7) 0.07
Susceptible 161 3 (1.9) 158 (98.1)
Ever received OFX during current episode
Yes 144 2 (1.4) 142 (98.6) 0.07
No 20 2 (10) 18 (90)
Ever received MOX during current episode
Yes 29 3 (10.3) 26 (89.7) 0.02
No 135 1 (0.7) 134 (99.3)

*FQ, fluoroquinolone; OFX, ofloxacin; MDR TB, multidrug-resistant tuberculosis; MOX, moxifloxicin
†Certain variables were tested for association but omitted from table because results were not statistically significant at α = 0.1.
‡Fisher exact test.
§Patients who did not receive treatment with the respective drug during the current episode of MDR TB were not included in the analysis.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external